Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 801–900 of 1,012
Baek, S. H., Ohgi, K. A., Nelson, C. A., Welsbie, D., Chen, C., Sawyers, C. L., Rose, D. W., & Rosenfeld, M. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510842103 · Cited by 81
ERβ a Novel Estrogen Receptor Offers the Potential for New Drug Development
Nilsson, S. V., Kuiper, G. G. J. M., & Gustafsson, J.-Α. (1998) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00096-4 · Cited by 93
Self-citationAntiestrogens: structure-activity relationships and use in breast cancer treatment
Traboulsi, T., Ezzy, M. E., Gleason, J. L., & Mader, S. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0024 · Cited by 90
“Overlay of X-ray structures of 4-hydroxytamoxifen (green) and raloxifene (aqua) bound to ERα (data from Shiau et al. (1998) and Brzozowski et al. (1997), respectively).”
BackgroundUmehara, K., Nemoto, K., Matsushita, A., Terada, E., Monthakantirat, O., De‐Eknamkul, W., Miyase, T., Warashina, T., Degawa, M., & Noguchi, H. (2009) · Journal of Natural Products · doi:10.1021/np900676y · Cited by 90
Computational studies and peptidomimetic design for the human p53–MDM2 complex
Zhong, H. A., & Carlson, H. A. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20275 · Cited by 90
Development of Peptide Antagonists That Target Estrogen Receptor β-Coactivator Interactions
Hall, J. M., Chang, C.-Y., & McDonnell, D. P. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.12.0561 · Cited by 83
Quaedackers, M. E., van den Brink, C. E., Wissink, S., Schreurs, R. H. M. M., Gustafsson, J.-Α., van der Saag, P. T., & van der Burg, B. (2001) · Endocrinology · doi:10.1210/endo.142.3.8003 · Cited by 90
Self-citationStructure–function relationships of vitamin D including ligand recognition by the vitamin D receptor
Yamada, S., Shimizu, M., & Yamamoto, K. (2002) · Medicinal Research Reviews · doi:10.1002/med.10023 · Cited by 90
Evaluation of Ligand-Dependent Changes in AR Structure Using Peptide Probes
Chang, C.-Y. (2002) · Molecular Endocrinology · doi:10.1210/me.16.4.647 · Cited by 80
Bamberg, K., Johansson, U., Edman, K., William‐Olsson, L., Myhre, S., Gunnarsson, A., Geschwindner, S., Aagaard, A., Granqvist, A., Jaisser, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193380 · Cited by 89
“For example, selective estrogen receptor (ER) modulators promote ligand specific ER conformations which translate into distinct co-factor recruitment and gene expression patterns [25, 26].”
BackgroundExperimental and Theoretical Electron Density Study of Estrone
Zhurova, E. A., Matta, C. F., Wu, N., Zhurov, V. V., & Pinkerton, A. A. (2006) · Journal of the American Chemical Society · doi:10.1021/ja061080v · Cited by 89
Charles, A. K., & Darbre, P. D. (2009) · Journal of Applied Toxicology · doi:10.1002/jat.1429 · Cited by 89
“The ligand binding domain (LBD) of the human oestrogen receptor alpha (ERα) seems able to accommodate a wide range of phenolic and ring structures where the molecules are mainly hydrophobic but with at least one relatively unhindered hydroxyl group (Brzozowski et al., 1997; Fang et al., 2001).”
BackgroundHistorical overview of nuclear receptors
Gustafsson, J.-Α. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.03.004 · Cited by 90
Self-citationNon-monotonic dose–response relationship in steroid hormone receptor-mediated gene expression
Li, L., Andersen, M. E., Heber, S., & Zhang, Q. (2007) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0003 · Cited by 90
“…that whether a receptor is able to recruit CoAor CoRdepends on its conformational changes after ligand binding, particularly in the LBD domain (Brzozowski et al. 1997, Shiau et al. 1998), and the phosphorylation status of the receptor also modulates this recruiting process (Atanaskova et al.…”
BackgroundInfluentialSchopfer, U., Schoeffter, P., Bischoff, S. F., Nozulak, J., Feuerbach, D., & Floersheim, P. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm015577l · Cited by 89
Leclerc, J., Meng, X., Delahaye, F., Leclerc, P., Baulieu, É.-É., & CATELLI, M. G. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.6.0121 · Cited by 91
Minireview: Dynamic Structures of Nuclear Hormone Receptors: New Promises and Challenges
Simons, S. S., Edwards, D. P., & Kumar, R. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1334 · Cited by 88
“Due to available LBD/AF2 crystal structures and the disordered nature of NTD/AF1, rational structure-based design of SRMs has been limited by necessity to how compounds modulate coregulatory protein interactions with AF2 (7), thereby neglecting AF1.”
BackgroundHlisníková, H., Petrovičová, I., Kolena, B., Šidlovská, M., & Sirotkin, A. V. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00215-5 · Cited by 89
“These are fragments of the ligand that bind to the NR [88, 89].”
BackgroundZhang, S., Jonklaas, J., & Danielsen, M. (2007) · Steroids · doi:10.1016/j.steroids.2007.03.012 · Cited by 88
Hoerer, S., Schmid, A., Heckel, A., Budzinski, R.-M., & Nar, H. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.10.033 · Cited by 88
Biobased phenol and furan derivative coupling for the synthesis of functional monomers
Decostanzi, M., Auvergne, R., Boutevin, B., & Caillol, S. (2019) · Green Chemistry · doi:10.1039/c8gc03541e · Cited by 88
Tremblay, G. B., Tremblay, A., Labrie, F., & Giguère, V. (1998) · PubMed · Cited by 88
Cheung, J., Mak, Y. T., Papaioannou, S., Evans, B. A., Fogelman, I., & Hampson, G. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770423 · Cited by 88
Cadmium a metalloestrogen: are we convinced?
Silva, N., Peiris-John, R. J., Wickremasinghe, R., Senanayake, H. M., & Sathiakumar, N. (2011) · Journal of Applied Toxicology · doi:10.1002/jat.1771 · Cited by 87
“The ligand binding domain (LBD) of the oestrogen receptor has an accessible molecular volume that is nearly twice that of the oestrogen molecular volume (Brzozowski et al., 1997).”
BackgroundMpamhanga, C. P., Chen, B., McLay, I. M., & Willett, P. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci050420d · Cited by 87
Katzenellenbogen, J. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200801h · Cited by 87
Identification of Xenoestrogens in Food Additives by an Integrated in Silico and in Vitro Approach
Amadasi, A., Mozzarelli, A., Meda, C., Maggi, A. C., & Cozzini, P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800048m · Cited by 88
“Agonists stabilize a receptor “closed” conformation with H12 packed against helices 3, 5, 6, and 11, thus sealing the binding site (Figure 1a), whereas SERMs and antagonists stabilize an “open” conformation, in which H12 occupies a portion of ERα coactivator binding groove (Figure 1b) (13, 14).”
BackgroundResultParent, A. A., Gunther, J. R., & Katzenellenbogen, J. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800698b · Cited by 81
Li, D., Li, T., Wang, F., Tian, H., & Samuels, H. H. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5782-5792.2002 · Cited by 87
“Helix 12 is an integral part of the LBD that is engaged in ligand binding (5, 44, 49, 51) and also plays an important role in ligand-induced dissociation of corepressors (6, 8) and/or recruitment of coactivators (11, 40, 49).”
BackgroundLoven, M. A., Likhite, V. S., Choi, I., & Nardulli, A. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106211200 · Cited by 79
Dostalova, P., Žatecká, E., & Komrsková, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050904 · Cited by 87
“The ligand-binding site of ERα has a volume of 450 Å3 and that of ERβ 390 Å3; however E2, as the natural ligand of ERs, has a volume of only 245 Å3 [171,172].”
BackgroundIsoflavones: their effects on cardiovascular risk and functions
Nestel, P. J. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200302000-00002 · Cited by 86
Roelens, F., Heldring, N., Dhooge, W., Bengtsson, M., Comhaire, F. H., Gustafsson, J.-Α., Treuter, E., & Keukeleire, D. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060692n · Cited by 86
Self-citationLiu, H., Park, W. C., Bentrem, D. J., McKian, K. P., Reyes, A. D. L., Loweth, J. A., Schafer, J. M., Zapf, J. W., & Jordan, V. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108335200 · Cited by 86
O’Neill, K. E., Chen, S., & Brinton, R. D. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.09.005 · Cited by 86
“Using electron crystallography, Brzozowski et al. (1997) demonstrated that while Ral enters the binding pocket of the estrogen receptor, the activation process is inhibited due to the molecular structure of Ral.”
BackgroundNuclear Hormone Receptor Coregulator: Role in Hormone Action, Metabolism, Growth, and Development
Mahajan, M., & Samuels, H. H. (2004) · Endocrine Reviews · doi:10.1210/er.2004-0012 · Cited by 86
Structural Basis for HNF-4α Activation by Ligand and Coactivator Binding
Duda, K., Chi, Y.-I., & Shoelson, S. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400864200 · Cited by 75
Beattie, M. S., Costantino, J. P., Cummings, S. R., Wickerham, D. L., Vogel, V. G., Dowsett, M., Folkerd, E. J., Willett, W. C., Wolmark, N., & Hankinson, S. E. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj011 · Cited by 81
Molecular Basis for the Constitutive Activity of Estrogen-related Receptor α-1
Chen, S., Zhou, D., Yang, C., & Sherman, M. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102638200 · Cited by 86
Hsu, C.-L., Chen, Y.-L., Yeh, S., Ting, H.-J., Hu, Y.-C., Lin, H., Wang, X., & Chang, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211908200 · Cited by 85
Molecular Mechanism of Action (MMoA) in Drug Discovery
Swinney, D. C. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00009-6 · Cited by 85
Rajbhandari, P., Finn, G., Solodin, N. M., Singarapu, K. K., Sahu, S. C., Markley, J. L., Kadunc, K. J., Ellison-Zelski, S. J., Kariagina, A., Haslam, S. Z., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06073-11 · Cited by 77
Bryant, H. U., Glasebrook, A. L., Yang, N., & Sato, M. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00147-2 · Cited by 85
Pietras, R. J. (2003) · The Breast Journal · doi:10.1046/j.1524-4741.2003.09510.x · Cited by 85
“On binding estradiol, ERα undergoes a change in the conformation of the ligand-binding domain to form a novel surface in the region of the C-terminal helix, helix 12 (46).”
BackgroundSuppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor
Wang, L., Yang, X. Y., Zhang, X., Mihalic, K., Fan, Y., Xiao, W., Howard, O. M. Z., Appella, E., Maynard, A. T., & Farrar, W. L. (2003) · Nature Medicine · doi:10.1038/nm969 · Cited by 85
Osz, J., Brélivet, Y., Peluso-Iltis, C., Cura, V., Eiler, S., Ruff, M., Bourguet, W., Rochel, N., & Moras, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118192109 · Cited by 84
“The dimerization interface involves residues from helices H7, H9 and H10 and loops L8-9 and L9-10 as previously described (19, 28) with a tilt of the dimer interface (Fig.”
MethodWinuthayanon, W., Piyachaturawat, P., Suksamrarn, A., Ponglikitmongkol, M., Arao, Y., Hewitt, S. C., & Korach, K. S. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0900613 · Cited by 84
“…that resides in the AF2 region on helix 12; because helix 12 of the ligand-binding domain forms part of a hydrophobic cavity of the receptor that is crucial for E2 agonist binding (Brzozowski et al. 1997), this mutation dampened the transcriptional activity of E2 as well as the diaryl heptanoids.”
BackgroundPicard, N., Charbonneau, C., Sanchez, M., Licznar, A., Busson, M., Lazennec, G., & Tremblay, A. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0281 · Cited by 84
“The mechanistic activation of AF-2 function by ligand has been well detailed for nuclear receptors and in particular, crystallographic studies of their ligand binding domains, such as those for ERc and ERd, have helped to identify the structural determinants involved (39-42).”
BackgroundBlondel, A., Renaud, J., Fischer, S., Moras, D., & Karplus, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2879 · Cited by 84
Androgen receptor–cofactor interactions as targets for new drug discovery
Chang, C., & McDonnell, D. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.002 · Cited by 85
Estrogenic/Antiestrogenic Activities of Benzo[a]pyrene Monohydroxy Derivatives.
Hirose, T., Morito, K., Kizu, R., Toriba, A., Hayakawa, K., Ogawa, S., Inoue, S., Muramatsu, M., & Masamune, Y. (2001) · Eisei kagaku · doi:10.1248/jhs.47.552 · Cited by 84
Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow
Jordan, V. C. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.13.967 · Cited by 84
Sun, J., Nawaz, Z., & Slingerland, J. M. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0082 · Cited by 83
Nonsteroidal FXR Ligands: Current Status and Clinical Applications
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83
Mboula, V. M., Hequet, V., Andrès, Y., Gru, Y., Colin, R., Doña-Rodríguez, J. M., Pastrana‐Martínez, L. M., Silva, A. M. T., Leleu, M. F., Tindall, A. J., et al. (2014) · Applied Catalysis B: Environmental · doi:10.1016/j.apcatb.2014.05.026 · Cited by 83
Zhao, L., O’Neill, K. E., & Brinton, R. D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.109504 · Cited by 83
“…from adopting either the characteristic agonist orientation, as seen with 17 -estradiol, in which helix 12 is aligned over the ligandbinding pocket (Brzozowski et al., 1997), or the AF-2 antagonist orientation, as seen with TMX and RAL, in which helix 12 orients along the coactivator binding…”
BackgroundInfluentialWang, L., Yang, X. Y., Zhang, X., An, P., Kim, H.-J., Huang, J., Clarke, R. C., Osborne, C. K., Inman, J. K., Appella, E., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.015 · Cited by 84
Bicchi, C. P., Schilirò, T., Pignata, C., Fea, E., Cordero, C. E. I., Canale, F., & Gilli, G. (2008) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2008.11.039 · Cited by 83
Jacobs, M. N., Dickins, M., & Lewis, D. F. V. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00021-9 · Cited by 83
Cameron, R. B., Beeson, C., & Schnellmann, R. G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00669 · Cited by 84
Couture, J., Legrand, P., Cantin, L., Luu-The, V., Labrie, F., & Breton, R. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00762-9 · Cited by 84
Loven, M. A., Muster, N., Yates, J. R., & Nardulli, A. M. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0280 · Cited by 74
Love, J. D., Gooch, J. T., Benko, S., Li, C., Nagy, L., Chatterjee, V. K. K., Evans, R. M., & Schwabe, J. W. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110869200 · Cited by 75
Martínez, L., Sonoda, M. T., Webb, P., Baxter, J. D., Skaf, M. S., & Polikarpov, I. (2005) · Biophysical Journal · doi:10.1529/biophysj.105.063818 · Cited by 83
Töröcsik, D., Szanto, A., & Nagy, L. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.02.002 · Cited by 82
Ng, H. W., Perkins, R., Tong, W., & Hong, H. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110908709 · Cited by 83
“Larger ligands that would not have been expected to fit into the ER binding pocket have been reported to bind to the ER pocket as a result of the formation of novel binding grooves [30,55].”
BackgroundBioassay-guided isolation of a new cytotoxic ceramide from Cyperus rotundus L.
Samra, R. M., Soliman, A. F., Zaki, A. A., Ashour, A. A., Al-Karmalawy, A. A., Hassan, M., & Zaghloul, A. M. (2021) · South African Journal of Botany · doi:10.1016/j.sajb.2021.02.007 · Cited by 82
Estrogen receptor-α signaling in post-natal mammary development and breast cancers
Rusidzé, M., Adlanmérini, M., Chantalat, É., Raymond‐Letron, I., Cayre, S., Arnal, J., Deugnier, M., & Lenfant, F. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03860-4 · Cited by 82
“Crystal structure revealed that the LBD has 12 alpha helices and E2-binding repositionnes helix 12, such that activation function AF-2 is exposed, allowing interactions with coregulators [77].”
BackgroundStructure and Function of the Glucocorticoid Receptor Ligand Binding Domain
Bledsoe, R. K., Stewart, E. L., & Pearce, K. H. (2004) · Vitamins and hormones · doi:10.1016/s0083-6729(04)68002-2 · Cited by 85
Tamura, H., Ishimoto, Y., Fujikawa, T., Aoyama, H., Yoshikawa, H., & Akamatsu, M. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.06.064 · Cited by 82
Liu, H., Lee, E. S., Reyes, A. D. L., Zapf, J. W., & Jordan, V. C. (2001) · PubMed · Cited by 83
Swamy, N., James, D. A., Mohr, S. C., Hanson, R. N., & Ray, R. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00242-0 · Cited by 82
Sauvé, F., McBroom, L. D. B., Gallant, J., Moraitis, A. N., Labrie, F., & Giguère, V. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.1.343-353.2001 · Cited by 84
“In particular, the bulkier side chains present in OHT and RAL prevent the AF-2 helix from folding normally and reposition it to the site of coactivator interaction, thus prohibiting coactivator binding (7, 53).”
BackgroundZhou, H.-B., Comninos, J. S., Stossi, F., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0506773 · Cited by 70
Treuter, E., Johansson, L., Thomsen, J. S., Wärnmark, A., Leers, J., Pelto-Huikko, M., Sjöberg, M., Wright, A. P. H., Spyrou, G., & Gustafsson, J.-Å. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6667 · Cited by 74
Self-citationYeh, S., Kang, H., Miyamoto, H., Nishimura, K., Chang, H., Ting, H., Rahman, M. M., Lin, H., Fujimoto, N., Hu, Y., et al. (1999) · Endocrine · doi:10.1385/endo:11:2:195 · Cited by 82
Norman, A. W. (1999) · Steroids · doi:10.1016/s0039-128x(98)00091-9 · Cited by 82
Effects of Organochlorine Pesticide Residues in Maternal Body on Infants
Qi, S., Xu, X.-L., Ma, W., Deng, S., Lian, Z.-X., & Yu, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.890307 · Cited by 81
“The C17-hydroxyl on the D ring is of equal importance during binding of E2 to ERs; it exhibits stable contact with His524 in ERa and His475 in Erb (114, 116, 117).”
BackgroundInfluentialHussain, M. K., Ansari, M. I., Yadav, N., Gupta, P. K., Gupta, A. K., Saxena, R., Fatima, I., Manohar, M., Kushwaha, P., Khedgikar, V., et al. (2014) · RSC Advances · doi:10.1039/c3ra45749d · Cited by 81
Cui, Y., Niu, A., Pestell, R. G., Kumar, R., Curran, E. M., Liu, Y., & Fuqua, S. A. W. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0063 · Cited by 81
“Upon hormone binding, this helix folds back and generates a transcriptionally-active conformation (26).”
BackgroundRenaud, J., Bischoff, S. F., Buhl, T., Floersheim, P., Fournier, B., Geiser, M., Halleux, C., Kallen, J., Keller, H., & Ramage, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040858p · Cited by 67
The first organometallic antioestrogens and their antiproliferative effects
Jaouen, G., Top, S., Vessières, A., Leclercq, G., Quivy, J. I., Jin, L., & Croisy, A. (2000) · Comptes Rendus de l Académie des Sciences - Series IIC - Chemistry · doi:10.1016/s1387-1609(00)00118-3 · Cited by 81
Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost
Lippman, S. M., & Brown, P. H. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1809 · Cited by 81
Different Molecular Mechanisms of Vitamin D3 Receptor Antagonists
Toell, A., González, M. M., Ruf, D., Steinmeyer, A., Ishizuka, S., & Carlberg, C. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12276-6 · Cited by 81
Barker, M. D., Clackers, M., Copley, R. C. B., Demaine, D. A., Humphreys, D. C., Inglis, G. G. A., Johnston, M. J. G., Jones, H. T., Haase, M. V., House, D., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060302x · Cited by 81
Gaskell, T. L., Robinson, L. L. L., Groome, N. P., Anderson, R. A., & Saunders, P. T. K. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020811 · Cited by 81
Wurtz, J., Guillot, B., Fagart, J., Moras, D., Tietjen, K., & Schindler, M. (2000) · Protein Science · doi:10.1110/ps.9.6.1073 · Cited by 79
“They are observed not only between structures of different NRs@ER ~Brzozowski et al., 1997; Shiau et al., 1998; Tanenbaum et al., 1998!, PPAR~Nolte et al., 1998!, PR ~Williams & Sigler, 1998!, RAR ~Renaud et al., 1995!, RXR ~Bourget et al., 1995!, TR ~Wagner et al., 1995!, VDR ~Rochel et al.,…”
BackgroundNeedham, M., Raines, S., McPheat, J., Stacey, C., Ellston, J., Hoare, S., & Parker, M. G. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00027-3 · Cited by 83
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer
Bak, M. J., Das Gupta, S., Wahler, J., & Suh, N. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.03.001 · Cited by 80
Khattab, M., & Al-Karmalawy, A. A. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0273 · Cited by 80
Schilirò, T., Pignata, C., Rovere, R., Fea, E., & Gilli, G. (2009) · Chemosphere · doi:10.1016/j.chemosphere.2008.12.028 · Cited by 80
Titanium dioxide mediated photocatalytic degradation of 17β-estradiol in aqueous solution
Mai, J., Sun, W., Xiong, L., Liu, Y., & Ni, J. (2008) · Chemosphere · doi:10.1016/j.chemosphere.2008.05.073 · Cited by 80
Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms
Lambert, M. N. T., Thorup, A. C. S., Hansen, E. S. S., & Jeppesen, P. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176590 · Cited by 80
Molecular classification of estrogens.
Jordan, V. C., Schafer, J. M., Levenson, A. S., Liu, H., Pease, K. M., Simons, L. A., & Zapf, J. W. (2001) · PubMed · Cited by 80
Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ERα
Dykstra, K. D., Guo, L., Birzin, E. T., CHAN, W. W.-S., Yang, Y. T., Hayes, E. C., DaSilva, C. A., Pai, L.-Y., Mosley, R. T., Kraker, B., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.054 · Cited by 80
Chiellini, G., Nguyen, N.-H., Apriletti, J. W., Baxter, J. D., & Scanlan, T. S. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00284-x · Cited by 79
Kumar, R., & Litwack, G. (2009) · Steroids · doi:10.1016/j.steroids.2009.07.012 · Cited by 79
Masiello, D., Chen, S., Xu, Y., Verhoeven, M. C., Choi, E., Hollenberg, A. N., & Balk, S. P. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0436 · Cited by 79
Li, X., Ye, L., Wang, X., Xinzhou, W., Liu, H., Qian, X., Zhu, Y., & Yu, H. (2012) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2012.08.072 · Cited by 79
“Considering the structural similarity of the native ligand and target compounds in this study, and the stability of the active pocket, the crystal structure of ERα LBD bound to 17β-estradiol (E2) (PDB code: 1ERE) (Brzozowski et al., 1997) was selected and used in the docking process.”
MethodA New Approach to Menopausal Therapy: The Tissue Selective Estrogen Complex
Komm, B. S. (2008) · Reproductive Sciences · doi:10.1177/1933719108325759 · Cited by 79
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.